Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6304326 | 0.90 | ALDH1A1 (0.37) | ADRB2ADRB1ADRB3ALDH1A1SMN1; SMN2 | |
| SCHEMBL7739829 | 0.84 | ADRB2 (0.37) | ADRB2ADRB1ADRB3ALDH1A1SMN1; SMN2 | |
| SCHEMBL7739823 | 0.84 | ADRB2 (0.37) | ADRB2ADRB1ADRB3ALDH1A1SMN1; SMN2 | |
| SCHEMBL6300649 | 0.83 | ADRB2 (0.35) | ADRB2ADRB1ADRB3ALDH1A1SMN1; SMN2 | |
| SCHEMBL6300641 | 0.83 | ADRB2 (0.35) | ADRB2ADRB1ADRB3ALDH1A1SMN1; SMN2 | |
| SCHEMBL6299529 | 0.83 | CRHBP (0.41) | ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL7742502 | 0.81 | CRHBP (0.42) | ALDH1A1SMN1; SMN2MMP1MMP2MMP9 | |
| SCHEMBL7742500 | 0.81 | CRHBP (0.42) | ALDH1A1SMN1; SMN2MMP1MMP2MMP9 | |
| SCHEMBL6300644 | 0.80 | MAPT (0.36) | ADRB2ADRB1ADRB3ALDH1A1SMN1; SMN2 | |
| SCHEMBL7740918 | 0.78 | OPRK1 (0.38) | ADRB2ADRB1ADRB3ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040002480-A1 | Aminobutyric acid derivatives and pharmaceutical composition containing the same as active ingredient | TAKAHASHI KANJI (JP) | 2004-01-01 | — | — | US | claimed |
| US-6569899-B1 | Such as 5-ethoxymethoxy-4(S)-(N-(4-iodophenylcarbonyl)amino) pentanoic acid methyl ester for inhibiting matrix metalloproteinase; for treatment of rheumatoid diseases, arthrosteitis, osteoarthritis, and osteoporosis | ONO PHARMACEUTICALS CO., LTD. (JP) | 2003-05-27 | — | — | US | claimed |
| US-6924307-B2 | Aminobutyric acid derivatives and pharmaceutical composition containing the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| US-20040002480-A1 | Aminobutyric acid derivatives and pharmaceutical composition containing the same as active ingredient | TAKAHASHI KANJI (JP) | 2004-01-01 | — | — | US | disclosed |
| US-6569899-B1 | Such as 5-ethoxymethoxy-4(S)-(N-(4-iodophenylcarbonyl)amino) pentanoic acid methyl ester for inhibiting matrix metalloproteinase; for treatment of rheumatoid diseases, arthrosteitis, osteoarthritis, and osteoporosis | ONO PHARMACEUTICALS CO., LTD. (JP) | 2003-05-27 | — | — | US | disclosed |
| EP-1167346-A1 | 4-AMINOBUTANOIC ACID DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002480-A1 | Aminobutyric acid derivatives and pharmaceutical composition containing the same as active ingredient | GABBR1, GABRB1, GABBR2 | ADRB2 136/4885ADRB1 73/4885ADRB3 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.